医学
内科学
乳腺癌
病态的
化疗
曲妥珠单抗
肿瘤科
阶段(地层学)
新辅助治疗
激素受体
癌症
胃肠病学
人口
生物
环境卫生
古生物学
作者
Sora Kang,So H. Lee,Hee Jun Lee,Hyehyun Jeong,Jae Ho Jeong,Jeong Eun Kim,Jin‐Hee Ahn,Kyung Hae Jung,Gyungyub Gong,Hak H. Kim,Sae Byul Lee,Jongwon Lee,Sung‐Bae Kim
标识
DOI:10.1016/j.ejca.2022.08.031
摘要
The interest in HER2-low breast cancer (BC) has increased in recent years with the development of novel anti-HER2 antibody-drug conjugates. Here, we investigated the clinical outcomes and relapse patterns of patients with HER2-low or -zero BCs in an Asian population.We retrospectively identified HER2-low or -zero BC patients with stage I-III tumours who were treated with neoadjuvant chemotherapy and underwent curative surgery, between 2014 and 2018 at Asan Medical Center, Seoul, Korea.A total of 818 and 754 HER2-zero and HER2-low BC patients, respectively, were consecutively included in this analysis. The HER2-low group had more hormone receptor [HR]-positive patients (81% versus 56%, P < 0.001). The HER2-zero group had a higher proportion of patients who achieved pathological complete response (pCR) (14.7% versus 9.8%, P = 0.003); however, no significant differences of pCR rate by HER2 status were identified in the HR-positive (P = 0.4) and HR-negative groups (P = 0.3) when analysed separately. The HER2-low BC cases had higher 5-year overall survival (OS) and disease-free survival (DFS) rates (P < 0.001 for OS; P = 0.002 for DFS); however, no differences were observed in terms of OS and DFS by HER2 status in the HR-positive group (P = 0.21 for OS and P = 0.66 for DFS).Our current findings do not support that HER2-low BC had different biology and clinical features compared to HER2-zero BC in patients who treated with neoadjuvant chemotherapy. However, the prognostic impact of HER2-low status in BC remains controversial; thus warranting further research.
科研通智能强力驱动
Strongly Powered by AbleSci AI